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A major cause of hyperglycemia in diabetic patients
is inappropriate hepatic gluconeogenesis. PGC-1a
is a master regulator of gluconeogenesis, and its
activity is controlled by various posttranslational
modifications. A small portion of glucose metabo-
lizes through the hexosamine biosynthetic pathway,
which leads to O-linked b-N-acetylglucosamine
(O-GlcNAc) modification of cytoplasmic and nuclear
proteins. Using a proteomic approach, we identified
a broad variety of proteins associatedwith O-GlcNAc
transferase (OGT), among which host cell factor C1
(HCF-1) is highly abundant. HCF-1 recruits OGT to
O-GlcNAcylate PGC-1a, and O-GlcNAcylation facili-
tates the binding of the deubiquitinase BAP1, thus
protecting PGC-1a from degradation and promoting
gluconeogenesis. Glucose availability modulates
gluconeogenesis through the regulation of PGC-1a
O-GlcNAcylation and stability by the OGT/HCF-1
complex. Hepatic knockdown of OGT and HCF-1
improves glucose homeostasis in diabetic mice.
These findings define the OGT/HCF-1 complex as
a glucose sensor and key regulator of gluconeogen-
esis, shedding light on new strategies for treating
diabetes.
INTRODUCTION
Glucose flux through the hexosamine biosynthetic pathway
(HBP) leads to the posttranslational modification of cytoplasmic,
nuclear, and mitochondrial proteins by O-linked b-N-acetylglu-
cosamine (O-GlcNAc), termed O-GlcNAcylation (Hart et al.,
2007; Torres and Hart, 1984). O-GlcNAcylation is emerging as
a key regulator of diverse cellular processes, such as signal226 Cell Metabolism 16, 226–237, August 8, 2012 ª2012 Elsevier Inctransduction, transcriptional regulation, and proteasomal degra-
dation (Yanget al., 2002; Zachara andHart, 2004, 2006). Aberrant
O-GlcNAcylation has been linked to a plethora of human
diseases, including diabetes, cancer, and neuronal diseases
(Lazarus et al., 2009; Ngoh et al., 2010; Slawson et al., 2010).
UDP-GlcNAc, the donor substrate, and O-GlcNAcylation
levels within the cell are modulated by the availability of
glucose, fatty acids, amino acids, and nucleotides. Therefore,
O-GlcNAcylation is proposed as a nutrient sensor and metabolic
regulator (Butkinaree et al., 2010; Hanover et al., 2012). Overex-
pression of the rate-limiting enzyme of the HBP, glutamine fruc-
tose-6-phosphate transaminase (GFAT), leads to peripheral
insulin resistance (Hebert et al., 1996; Veerababu et al., 2000).
Transgenic mice overexpressing O-GlcNAc transferase (OGT)
in skeletal muscle and fat exhibit elevated circulating insulin
levels and insulin resistance (McClain et al., 2002). Key compo-
nents of insulin signaling can be O-GlcNAcylated (Whelan
et al., 2010), and O-GlcNAcylation has been shown to be a
negative regulator of insulin signaling (Yang et al., 2008).
Hyperglycemia is also associated with O-GlcNAcylation of tran-
scription factors and cofactors. O-GlcNAcylation of FOXO1,
CRTC2, and PGC-1a modulate expression of gluconeogenic
genes (Dentin et al., 2008; Housley et al., 2008, 2009; Kuo
et al., 2008). Chronic increases in the levels of PDX1 and
NeuroD1 O-GlcNAcylation may contribute to hyperinsulinemia
in type 2 diabetes (Andrali et al., 2007; Gao et al., 2003). Thus,
O-GlcNAc signaling is believed to serve as a nexus between
nutrient flux, insulin resistance, and diabetes.
Unlike the presence of hundreds of protein kinases and phos-
phatases in the human genome, O-GlcNAc cycling is modified
only by one O-GlcNAc transferase (OGT) and one O-GlcNAcase
(OGA). It is largely unknown how the substrate specificity of
OGT and OGA is achieved. It has been proposed that OGT
recognizes substrates primarily though the tandem tetratrico-
peptide repeats (TPRs). Indeed, different OGT isoforms with
various lengths in TPRs show different substrate specificities.
Another possibility is that OGT forms dynamic holoenzymes
with various protein partners that facilitate substrate recognition.
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OGT/HCF-1/PGC-1a Signaling in Gluconeogenesis(Butkinaree et al., 2010; Chikanishi et al., 2010). For instance,
interaction of OGT and p38MAPK activates O-GlcNAcylation of
neurofilament H (Cheung and Hart, 2008). We hypothesize that
OGT recognizes its substrates by association with a hierarchy
of highly conserved adaptor proteins, analogous to the ubiquitin
system in which dual E1 enzymes interact with dozens of E2 and
hundreds of E3 ligases for substrate recognition.
In this study, we show that OGT and its interacting protein
host cell factor C1 (HCF-1) cooperatively upregulate gluconeo-
genesis by stabilizing PGC-1a. O-GlcNAcylation of PGC-1a
decreases its ubiquitination by recruiting the deubiquitinase
BAP1.Glucose homeostasis in diabetic animals canbe improved
by knocking down OGT and HCF-1 in liver. Hence, OGT and
HCF-1 may serve as potential targets for treating diabetes.
RESULTS
Proteome-wide Analysis Identifies HCF-1 and PGC-1a
as OGT-Interacting Proteins
To identify candidate adaptor proteins that mediate substrate
recognition of OGT on a proteome-wide level, we performed
tandem affinity purification of OGT-binding proteins in HEK293T
cells (Figure S1A). Purified proteins were then identified by
Multidimensional Protein Identification Technology (MudPIT)
(Washburn et al., 2001) and subjected to pathway analysis using
MetaCore software (Figure 1A). A total of 853 putative OGT-
interacting proteins involved in a wide range of biological
processes were identified (Table S1). Strikingly, a large majority
of these proteins participate in signal transduction and metabo-
lism, supporting the notion that O-GlcNAcylation is a sensor and
regulator of metabolic homeostasis.
One of the highly abundant proteins copurified with OGT is
HCF-1 (Figure 1B). HCF-1 is an essential transcriptional
cofactor that has been shown to be required for herpes virus
gene expression, cell-cycle regulation, and stem cell growth
(Dejosez et al., 2010; Julien and Herr, 2003; Peng et al., 2010).
Consistent with previous reports (Capotosti et al., 2011; Daou
et al., 2011), coimmunoprecipitation analysis of endogenous
proteins confirms the interaction of OGT and HCF-1 and shows
that HCF-1 is highly O-GlcNAcylated (Figures 1C and S1B).
HCF-1 exists as a complex of the N- and C-terminal fragments
that result from proteolytic processing of the precursor protein
(Wilson et al., 1993). We found that both the N- and C-terminal
fragments of HCF-1 interact with OGT and are O-GlcNAcylated
(Figures S1C and S1D).
PGC-1a is a key transcriptional coactivator that regulates
mitochondrial biogenesis and hepatic gluconeogenesis (Fernan-
dez-Marcos and Auwerx, 2011). PGC-1a harbors a HCF-1
binding motif (HBM) (Lin et al., 2002). A proteomic approach to
identify PGC-1a-interacting proteins shows that HCF-1 and
OGT are among them (Figures 1D and S1E). Coimmunoprecipi-
tation analysis confirms the interaction between PGC-1a and
HCF-1 overexpressed in HEK293T cells and demonstrates
O-GlcNAcylation of PGC-1a (Figure 1E). It is known that PGC-1a
is strongly induced in liver during fasting (Puigserver et al., 2003).
To test the endogenous interactions between these proteins,
HCF-1 was immunoprecipitated from the liver of mice after
24 hr fasting. The results show that both OGT and PGC-1a are
enriched in the HCF-1 immunoprecipitate (Figure 1F). After 3 hrCelrefeeding, the PGC-1a level is largely reduced, which is coinci-
dent with a decreased interaction between HCF-1 and OGT (Fig-
ure 1F). O-GlcNAcylation of PGC-1a is also evident in fasted
mouse liver (Figure 1F). Taken together, these observations
suggest that OGT/HCF-1 complex formation and O-GlcNAcyla-
tion of PGC-1a are sensitive to food availability.
OGT and HCF-1 Cooperatively Regulate
Gluconeogenesis
Next, we examined the functional consequence of the OGT/
HCF-1 complex on PGC-1a. The presence of HCF-1 increases
the transcriptional activity of PGC-1a, which is further
augmented by OGT (Figure 2A). It has been known that PGC-
1a coactivates FOXO1 via the insulin response sequence (IRS)
to induce the expression of gluconeogenic genes such as
glucose-6-phosphatase (G6pc) and phosphoenolpyruvate car-
boxykinase (Pck1) (Puigserver et al., 2003). We show that OGT
and HCF-1 synergistically upregulate FOXO1 activity on both
the G6pc promoter (Figure 2B) and the synthetic IRS DNA
binding element (Figures S2A and S2B). Such synergistic effect
on FOXO1 activity is abolished by PGC-1a knockdown (Fig-
ure 2C). Overexpression of either the N- or C-terminal fragment
of HCF-1 has an effect similar to the precursor HCF-1 (Figures
S2C and S2D). We further show that the synergistic induction
ofG6pc promoter activity by OGT and HCF-1 is more dependent
on FOXO1 than other factors such as CREB/CRTC2, despite the
fact that OGT can promote CRTC2 activity (Dentin et al., 2008)
(Figures S2E–S2G). PGC-1a also coactivates HNF4a to regulate
gluconeogenic genes (Yoon et al., 2001). We found that OGT and
HCF-1 coexpression can promote the activity of the HNF4a
responsive reporter as well (Figures S2H and S2I), suggesting
a general effect of OGT/HCF-1 on PGC-1a regulation.
Chromatin immunoprecipitation was performed to detect
O-GlcNAc and HCF-1 at the promoter of the G6pc gene. Both
O-GlcNAc and HCF-1 are highly enriched in the FOXO1/HNF4a
binding region of the G6pc promoter (Figures 2D and 2E). To
test the effects of OGT and HCF-1 on expression of endogenous
gluconeogenic genes, adenoviruses encoding OGT and HCF-1
were used to infect hepatoma FAO cells (Figure 2F). Overexpres-
sion of either OGT or HCF-1 stimulates endogenous G6pc and
Pck1 expression, and coexpression of the two proteins has
a cooperative effect (Figures 2G and 2H). By measuring glucose
secretion into the culture medium, we also observed a coopera-
tive effect of OGT and HCF-1 on glucose output (Figure 2I). On
the other hand, knockdown of OGT and HCF-1 in FAO cells by
adenoviruses encoding the corresponding shRNAs (Figure 2J)
decreases gluconeogenic gene expression (Figures 2K and 2L)
and glucose production (Figure 2M). Treatment of FAO cells
with PUGNAc, a potent OGA inhibitor that increases global
O-GlcNAcylation levels, also significantly increases gluconeo-
genic gene expression and glucose output (Figures S2J and
S2K). Collectively, these results indicate that the OGT/HCF-1
complex promotes glucose production in hepatocytes.
O-GlcNAcylation and HCF-1 Interaction Stabilize
PGC-1a
An O-GlcNAcylation site of PGC-1a (Ser333) was previously
identified; however, the functional role of this site was not fully
determined (Housley et al., 2009). Here we show that PUGNAcl Metabolism 16, 226–237, August 8, 2012 ª2012 Elsevier Inc. 227
Figure 1. Identification of OGT/HCF-1/PGC-1a Protein Complex
(A) Pie chart of functional distribution of identified putative OGT-binding proteins.
(B) The top of the list of putative OGT-binding proteins. Spectrum counts in GFP and OGT samples are shown.
(C) The interaction between OGT and HCF-1 was confirmed by coimmunoprecipitation of endogenous proteins from hepatoma FAO cells. A total of 0.1 M free
GlcNAc was added to control for the specificity of O-GlcNAc antibody.
(D) List of top proteins identified in PGC-1a complex purification.
(E) HEK293T cells were cotransfected with HA-tagged PGC-1a and V5-tagged HCF-1, and their interaction and PGC-1a O-GlcNAcylation were determined.
(F) Interactions of HCF-1 with OGT and PGC-1a (middle) and O-GlcNAcylation of PGC-1a (top) in the livers from 24 hr-fasted and 3 hr-refed mice are shown.
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OGT/HCF-1/PGC-1a Signaling in Gluconeogenesistreatment increases PGC-1a O-GlcNAcylation, and mutation
of Ser333 to Ala (S333A) substantially decreases PGC-1a
O-GlcNAcylation (Figure 3A). Although the S333A mutation
does not affect the transcriptional activity, phosphorylation, or
subcellular localization of PGC-1a (Figures S3A–S3C) (Roth228 Cell Metabolism 16, 226–237, August 8, 2012 ª2012 Elsevier Incet al., 2009), elevating the O-GlcNAc level by PUGNAc increases
PGC-1a stability. In contrast, the S333A mutant shows slightly
decreased stability and is refractory to PUGNAc treatment
(Figures 3B and S3D). PGC-1a can be targeted for ubiquitin-
mediated proteolysis (Olson et al., 2008; Trausch-Azar et al.,.
Figure 2. OGT and HCF-1 Cooperatively Upregulate Gluconeogenesis
(A and B) Luciferase assays were performed in HepG2 cells; luciferase activity was normalized to cotransfected b-Gal activity. (A) Gal4-PGC-1a transactivation
assay (n = 3). (B) G6pc-luciferase assay in the absence or presence of FOXO1 (n = 3).
(C) G6pc-luciferase assay following infection of FOXO1-transfected FAO cells with adenovirus encoding PGC-1a shRNA or scrambled control shRNA
(n = 3).
(D and E) Chromatin immunoprecipitation assays of primary hepatocytes using O-GlcANc (D) and HCF-1 (E) antibodies (n = 3). IgG served as a negative control.
Real-time PCR was performed with primers flanking FOXO1/HNF4a binding region or 30 UTR (a negative control) of the G6pc gene.
(F–M) FAO cells were infected with overexpression (F–I) or knockdown (J–M) adenoviruses as indicated, then protein expression (F and J), G6pc (G and K), and
Pck1 (H and L) gene expression and glucose output (I and M) were determined (n = 3). All values represent mean ± SEM of data from three independent
experiments. *p < 0.05; **p < 0.01; ***p < 0.001 by ANOVA with a Bonferroni’s post hoc test compared with the vector control (A, B, G–I, and K–M). *p < 0.05 by
Student’s t test (C–E).
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OGT/HCF-1/PGC-1a Signaling in Gluconeogenesis2010). We found that OGT overexpression, which increases
PGC-1aO-GlcNAcylation (Figure S3E), decreases ubiquitination
of PGC-1a. While the S333A mutant has a dramatic increase in
ubiquitination compared with the wild-type (Figure 3C), OGT
overexpression still slightly decreases ubiquitination of the
S333A mutant, suggesting the existence of other potential
O-GlcNAcylation sites (also see Figure 3A). Moreover, the
S333Amutant has less ability to induceG6pc andPck1 transcrip-
tion compared with the wild-type (Figure S3F). Taken together,
these data indicate that O-GlcNAcylation protects PGC-1a
from proteasomal degradation.
Because HCF-1 and OGT have a cooperative effect on PGC-
1a activity and gluconeogenic gene expression (Figure 2), weCelhypothesized that HCF-1 is an adaptor protein for targeting
OGT to PGC-1a. To test this, a Y385A mutation in the HCF-1
binding motif (HBM) of PGC-1a (PGC-1aHBMmt) was generated.
The PGC-1aHBMmt protein shows no change in transcriptional
activity, phosphorylation, or localization (Figures S3A–S3C).
Indeed, PGC-1aHBMmt does not bind to HCF-1, and strikingly,
it is devoid of O-GlcNAcylation (Figure 3D). Compared with the
wild-type, PGC-1aHBMmt exhibits increased ubiquitination in
the presence of MG132 (Figure 3E). HCF-1 overexpression
increases the stability of wild-type PGC-1a, but has no effect
on the PGC-1aHBMmt protein (Figures 3F and S3G). These data
argue that HCF-1 binding promotes O-GlcNAcylation and
stability of PGC-1a.l Metabolism 16, 226–237, August 8, 2012 ª2012 Elsevier Inc. 229
Figure 3. O-GlcNAcylation and HCF-1
Stabilize PGC1a
(A and B) HEK293T cells were transfected and
treated as indicated. (A) O-GlcNAcylation of WT
and S333A mutant PGC-1a. (B) Stability of PGC-
1awas determined by treatment of cycloheximide
(CHX), an inhibitor of protein synthesis. Relative
half-lives are shown in Figure S3D.
(C) Ubiquitination of WT and S333A PGC-1a
treated with proteasome inhibitor MG132.
(D) O-GlcNAcylation and HCF-1 interaction of
PGC-1aHBMmt protein.
(E) Ubiquitination of PGC-1aHBMmt protein.
(F) Stability of WT and HBMmt PGC-1a in the
presence or absence of HCF-1. Relative half-lives
are shown in Figure S3G.
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OGT/HCF-1/PGC-1a Signaling in GluconeogenesisOGT/HCF-1 Complex Mediates Regulation
of Gluconeogenesis by Glucose
Hormones such as insulin, glucagon, and glucocorticoids tightly
control glucose homeostasis. Although insulin, forskolin (a cAMP
agonist mimicking the action of glucagon), and dexamethasome
(a synthetic glucocorticoid) are potent regulators of gluconeo-
genic gene expression (Figures S4A and S4B), our results
show that they do not modulate the association between OGT
and HCF-1 (Figure S4C). It has been known that glucose itself
regulates gluconeogenesis (Rigoulet et al., 1987; Sacca et al.,
1978; Seglen, 1974). However, the underlying mechanism is still
obscure. Consistent with previous in vivo studies (Rigoulet et al.,
1987), we show that glucose treatment can directly modulate
gluconeogenesis in primary hepatocytes, with a maximal effect
observed at 5 mM glucose (Figure 4A). Consistent with this
observation, the expression ofG6pc and Pck1 is also modulated
by glucose availability, with the peak level at 5 mM glucose
(Figures 4B and 4C). Since O-GlcNAc is a glucose sensor, we
tested whether OGT/HCF-1 complex formation responds to
glucose availability. Interestingly, OGT/HCF-1 interaction peaks
under euglycemic conditions, although their expression levels
are relatively constant at different glucose concentrations (Fig-
ure 4D). The levels of PGC-1a proteins also peak at 5 mM
glucose (Figure 4D). Following treatment with MG132, which
blocks protein degradation and normalizes PGC-1a levels, we
observed that PGC-1a O-GlcNAcylation reaches its maximum
level at 5 mM glucose (Figure 4E). Chromatin immunoprecipita-
tion assays also show that O-GlcNAc and HCF-1 are most abun-
dant at the G6pc promoter upon 5 mM glucose treatment
(Figures 4F, 4G, S4D, and S4E). These findings suggest that230 Cell Metabolism 16, 226–237, August 8, 2012 ª2012 Elsevier Inc.the OGT/HCF-1 complex senses glucose
availability, thereby regulating PGC-1a
stability and glucose production.
Knockdown of OGT and HCF-1
Decreases Gluconeogenesis
To determine whether OGT/HCF-1
regulates gluconeogenesis in a PGC-
1a-dependent manner, primary hepato-
cytes from fed mice were infected with
adenoviruses encoding shRNAs target-
ing OGT and/or HCF-1. The efficacy ofOGT and HCF-1 knockdown was validated by examining their
mRNA and protein levels (Figures 5A and S5A). Along with the
observation that PGC-1a expression is not detectable in fed
mice (Figure 5A), OGT and/or HCF-1 knockdown has no effect
on expression of gluconeogenic genes G6pc and Pck1 (Fig-
ure 5B). However, OGT and/or HCF-1 knockdown can signifi-
cantly suppress the expression of gluconeogenic genes induced
by PGC-1a overexpression (Figure 5B). As PGC-1a expression is
induced in primary hepatocytes from overnight-fasted mice,
OGT and/or HCF-1 knockdown significantly suppresses G6pc
expression, which is abrogated by PGC-1a knockdown (Fig-
ure S5B). Compared with fed mice, we observed the increased
occupancies of O-GlcNAc and HCF-1 at the FOXO1/HNF4a
binding region of the hepatic G6pc promoter in fasted mice
(Figures 5C and 5D). Taken together, these data show that the
modulation of gluconeogenic gene expression by OGT and
HCF-1 is dependent on PGC-1a.
To examine the physiological function of OGT/HCF-1, adeno-
viruses encoding shRNAs were delivered to the liver of C57BL/6
mice by systemic injection to knock down OGT and/or HCF-1
(Figure 5E). No significant difference in the expression of inflam-
matory markers Tnfa and Ifng in the liver was observed (Fig-
ure S5C). Pyruvate tolerance tests were performed to assess
gluconeogenesis (Figure 5F). Compared with the scrambled
shRNA control, OGT shRNA mice show an initial decrease in
blood glucose, but maintain high levels after 60 min (Figure 5F),
which may be due to their glucose intolerance (Figure 5G). OGT/
HCF-1 double knockdown decreases glucose production from
pyruvate to the extent similar to HCF-1 knockdown, suggesting
that the effect of OGT on gluconeogenesis is dependent on
Figure 4. Glucose Availability Regulates Gluconeogenesis andOGT/
HCF-1 Complex Formation
(A) Primary hepatocytes from 24 hr-fasted mice were treated with gluconeo-
genic medium containing 13C pyruvate, lactate, and different levels of glucose.
Newly synthesized glucose was calculated based on the distribution of
glucose M+1 isotopomers (n = 3).
(B and C) FAO cells were treated with medium containing different levels of
glucose for 6 hr, and G6pc (B) and Pck1 (C) transcripts were determined by
real-time PCR (n = 3).
(D) Immunoprecipitation of endogenous HCF-1 from protein lysates of FAO
cells treatedwith different levels of glucose. Relative recovery of OGT in HCF-1
immunoprecipitation is shown at right.
(E) FAO cells were infected with Flag/HA-PGC-1a adenovirus. MG132
was added during the glucose treatment to equalize PGC-1a expression.
O-GlcNAcylation levels of PGC-1a were determined, with the densitometric
values shown at right (n = 3).
(F and G) Primary hepatocytes were treated with different levels of glucose for
6 hr. The association of O-GlcNAc (F) and HCF-1 (G) on the G6pc promoter
was determined by chromatin immunoprecipitation (n = 3). All values represent
mean ± SEM from three independent experiments. *p < 0.05; **p < 0.01; ***p <
0.001 by ANOVA with a Bonferroni’s post hoc test compared with 5 mM
glucose.
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OGT/HCF-1/PGC-1a Signaling in GluconeogenesisHCF-1 (Figure 5F). Although OGT shRNA mice are glucose intol-
erant, and HCF-1 shRNA mice behave similarly to the control,
mice with OGT/HCF-1 double knockdown show improved
glucose tolerance (Figure 5G). No significant difference in serumCelinsulin was observed between the different groups (Figure S5D).
Basal glucose levels are lower in the double knockdown mice,
further indicating a gluconeogenic defect (Figure S5E). However,
there is no statistically significant difference in insulin sensitivity
between those mice (Figure S5F). In further support of our
hypothesis, OGT and HCF-1 knockdown decreases PGC-1a
protein levels (Figure 5E) and expression of gluconeogenic
genes in the liver (Figure 5H). Consistent with the role of PGC-
1a as a master regulator of genes involved in fatty acid oxidation
and mitochondrial biogenesis, we observed decreased expres-
sion of genes in fatty acid oxidation and mitochondrial respira-
tion in the liver following OGT/HCF-1 double knockdown (Fig-
ure S5G). Taken together, these results strongly argue that
OGT/HCF-1 knockdown in C57BL/6 mice can suppress gluco-
neogenesis through the downregulation of PGC-1a.
O-GlcNAcylation Recruits BAP1 to Deubiquitinate
PGC-1a
BAP1, a deubiquitinating enzyme, has been shown to interact
with HCF-1 (Figure 6A), yet its targets are largely unknown
(Machida et al., 2009; Misaghi et al., 2009). We tested the
hypothesis that BAP1 is responsible for PGC-1a deubiquitina-
tion. Overexpression of BAP1 does not increase global ubiquiti-
nation, but substantially increases the level of PGC-1a and
decreases PGC-1a ubiquitination as normalized to the protein
level (Figure 6B). This suggests that the regulation of PGC-1a
by BAP1 is target specific. PUGNAc treatment promotes the
interaction between PGC-1a and BAP1, while it has no effect
on the S333A mutant (Figure 6C), suggesting that O-GlcNAcyla-
tion of PGC-1a facilitates BAP1 binding. Overexpression of OGT,
HCF-1, and BAP1 individually or in combination enhances PGC-
1a stability (Figure 6D). OGT, HCF-1, and BAP1 stabilize PGC-1a
by blocking its ubiquitination (Figure 6E). Conversely, knock-
down of BAP1 in cells (Figure S6A) decreases the stability of
PGC-1a (Figure 6F). In agreement with others’ observations
(Daou et al., 2011), we noticed that HCF-1 can stabilize OGT
(Figures 6E and S6B). BAP1 also increases OGT protein levels,
suggesting that BAP1 is a potential deubiquitinase for OGT as
well (Figure S6C). These data indicate that HCF-1 recruits OGT
to O-GlcNAcylate PGC-1a, which facilitates the recruitment of
BAP1 to deubiquitinate PGC-1a and OGT, thereby sustaining
levels of PGC-1a in the cell.
Interestingly, Bap1 gene expression is significantly increased
in high fat diet (HFD) and db/db mice (Figure 6G). To further
determine the physiological role of BAP1 in gluconeogenesis,
Flag-tagged BAP1 was overexpressed in mouse liver by adeno-
viral infection. In line with our observation that BAP1 is a deubi-
quitinase for PGC-1a in vitro, hepatic BAP1 overexpression
increases the protein level of PGC-1a (Figure 6H). Furthermore,
BAP1-overexpressing mice show increased expression of
Pck1 transcripts (Figure 6I) and increased gluconeogenesis as
seen in the pyruvate tolerance test (Figure 6J). These data
demonstrate that BAP1 deubiquitinase stabilizes PGC-1a and
promotes gluconeogenesis in vivo.
Knockdown of OGT and HCF-1 Improves Glucose
Homeostasis in Diabetic Mice
Insulin resistance and diabetes are associated with increased
O-GlcNAc modification (Cooksey and McClain, 2002; Hartl Metabolism 16, 226–237, August 8, 2012 ª2012 Elsevier Inc. 231
Figure 5. OGT/HCF-1 Regulates Gluconeo-
genesis in a PGC-1a-Dependent Manner
(A and B) Primary hepatocytes from fed C57BL/6
mice (n = 3) were infected with adenoviruses
indicated. (A) Protein and (B) mRNA levels were
determined by western blotting and real-time
PCR, respectively.
(C and D) Chromatin immunoprecipitation of (C)
O-GlcNAc and (D) HCF-1 on the G6pc promoter
from primary hepatocytes of fed or fasted mice.
Antibody plus 0.1 M free GlcNAc (C) and rabbit
IgG (D) served as negative controls, respectively.
The relative signal to the control is shown.
(E–H) Twelve-week-old C57BL/6 male mice (n =
4–6) were injected with shRNA adenoviruses
through tail vein. Protein expression (E, day 3),
pyruvate tolerance test (F, day 3), glucose toler-
ance test (G, day 5), and gluconeogenic gene
expression (H, day 7) were determined. *, #, p <
0.05; **p < 0.01; ***p < 0.001 by ANOVA with a
Bonferroni’s post hoc test compared with scram-
bled shRNA. All values represent mean ± SEM.
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OGT/HCF-1/PGC-1a Signaling in Gluconeogenesiset al., 2011). We observed an increase in OGT expression
and global O-GlcNAcylation in the liver of HFD mice (Figures
7A, S7A, and S7C). Although hepatic OGT expression is
slightly decreased in genetically diabetic db/db mice, global
O-GlcNAcylation is increased, suggesting a possible increase
in OGT activity (Figures 7A, S7B, and S7D). Interestingly,
HCF-1 protein levels are also significantly elevated in both HFD
and db/db mice (Figures 7B and S7E). To evaluate whether
OGT/HCF-1 knockdown ameliorates diabetes, shRNA adenovi-
ruses were administered to db/db mice. No significant differ-
ences in expression of inflammatory genes were observed
between the different groups (Figure S7F). Individual knockdown
of OGT or HCF-1 improves glucose homeostasis, and double
knockdown further normalizes blood glucose, as shown by the
glucose tolerance test (Figure 7C). Insulin sensitivity is relatively
unchanged (Figure S7G). The salutary effects of OGT/HCF-1
knockdown in db/db mice can be attributed, at least in part, to
the suppression of gluconeogenesis through the downregulation
of G6pc expression (Figure 7D). These results suggest that the
OGT/HCF-1 complex may contribute to the pathogenesis of
diabetes by upregulating gluconeogenesis in vivo.
DISCUSSION
PGC-1a is a critical metabolic node subjected to both transcrip-
tional and posttranslational regulation (Fernandez-Marcos and232 Cell Metabolism 16, 226–237, August 8, 2012 ª2012 Elsevier Inc.Auwerx, 2011). The expression of PGC-
1a can be stimulated by exercise, cold,
and fasting through Ca2+, p38MAPK,
AMPK, and PKA pathways (Fernandez-
Marcos and Auwerx, 2011). The activity
of PGC-1a is fine-tuned by phos-
phorylation, acetylation, and methylation.
PGC-1a has also been shown to be
O-GlcNAcylated (Housley et al., 2009),
and PGC-1a acts to target OGT to
FOXO1 and FOXO3, resulting in theirincreased O-GlcNAcylation and transcriptional activity. Never-
theless, the role of O-GlcNAcylation on PGC-1a remains elusive.
In this study, we show that O-GlcNAcylation of PGC-1a can
stabilize PGC-1a by inhibiting its ubiquitination. PGC-1a can
be regulated by ubiquitin-dependent proteasomal degradation
(Olson et al., 2008; Trausch-Azar et al., 2010). Skp1/Cullin/
F-box-cell division control 4 (SCFCdc4) was identified as the E3
ubiquitin ligase for PGC-1a. Here, we identify BAP1, a member
of ubiquitin C-terminal hydrolases, as the PGC-1a deubiquiti-
nase. This suggests that a dynamic balance of ubiquitination
and deubiquitination is a key mechanism controlling cellular
PGC-1a levels. Along with the findings by Housley et al., it is
conceivable that O-GlcNAcylation of PGC-1a and FOXO tran-
scription factors may have sequential and concerted action in
promoting gluconeogenesis.
Interplay between O-GlcNAcylation and phosphorylation has
beenwell documented (Zeidan andHart, 2010). These twomodi-
fications can either competitively occupy single or proximal sites
or coexist at different sites to cooperatively regulate protein
functions. The copurification of protein kinase(s) and phospha-
tase(s) with OGT and OGA also suggests an intrinsic relationship
between O-GlcNAcylation and phosphorylation (Slawson et al.,
2008; Wells et al., 2004). However, a central question yet to be
answered is whether and how O-GlcNAcylation interplays with
other posttranslational modifications. An important study by
the Lefebvre group reveals that O-GlcNAcylation can positively
Figure 6. O-GlcNAcylation and HCF-1
Recruits BAP1 to Deubiquitinate PGC-1a
(A–F) HEK293T cells were transfected and treated
as indicated. (A) BAP1 interacts with HCF-1. (B)
Ubiquitination of PGC-1a was determined with/
without BAP1 overexpression. Relative level of
ubiquitination normalized to the protein level is
shown. (C) Interaction between PGC-1a and BAP1
was examined by the recovery of PGC-1a from
metal affinity purification of His-tagged BAP1. (D)
Stability and (E) ubiquitination of PGC-1a are
shown when cotransfected with OGT, HCF-1,
and BAP1. Relative ubiquitination normalized to
protein level is shown under the antiubiquitin blot.
(F) Stability of PGC-1a in response to BAP1
knockdown. Knockdown efficiency is shown in
Figure S6A.
(G) BAP1 gene expression in HFD and db/dbmice
compared to age-matched wild-type mice re-
vealed by real-time PCR (n = 4–5).
(H–J) Twelve-week-old C57BL/6 male mice (n = 4)
were injected with GFP or f-BAP1 adenoviruses
through tail vein. Protein expression (H, day 5),
Pck1 gene expression (I, day 5), and pyruvate
tolerance test (J, day 3) were determined. *p <
0.05; ***p < 0.001 by two-tailed t test for (G) and (I).
*p < 0.05 by ANOVA with a Bonferroni’s post hoc
test compared with the control for (J). All values
represent mean ± SEM.
Cell Metabolism
OGT/HCF-1/PGC-1a Signaling in Gluconeogenesisregulate global protein ubiquitination (Guinez et al., 2008). Here
we report that O-GlcNAcylation of PGC-1a does not affect
phosphorylation, but antagonizes ubiquitination of PGC-1a by
recruiting the deubiquitinase BAP1 (Figure 6). This is the first
evidence for a direct crosstalk between O-GlcNAcylation and
ubiquitination on a single protein. Previous studies show that
O-GlcNAcylation can modulate proteasome function (Guinez
et al., 2008; Zhang et al., 2003). However, this is unlikely to
account for the stabilization of PGC-1a by OGT because (1) the
S333Amutation, which bypasses the effects of O-GlcNAcylation
on the proteasome, increases PGC-1a ubiquitination and
decreases its stability, and (2) HCF-1 and BAP1 have no effect
on proteasome function or global ubiquitination (Figure 6B and
data not shown), but can decrease PGC-1a ubiquitination and
increase its stability.
HCF-1 has been identified in complex with OGT in different
contexts (Fujiki et al., 2009; Mazars et al., 2010; Wysocka
et al., 2003). Recent studies show that O-GlcNAcylation ofCell Metabolism 16, 226–23HCF-1 is required for its proteolytic matu-
ration, and OGT itself is suggested as the
protease that catalyzes HCF-1 cleavage
(Capotosti et al., 2011; Daou et al.,
2011). Approximately 50% of nuclear
OGT is associated with HCF-1, yet the
targets and functions of this abundant
nuclear complex are poorly understood
(Daou et al., 2011). HCF-1 is known as
a scaffold protein for multiple histone-
modifying enzymes (Kristie et al., 2010).
We also identified that a variety of
enzymes that catalyze diverse posttrans-lational modifications are associated with OGT and/or HCF-1
(Table S1 and data not shown). Drosophila OGT is one of the
polycomb group genes involved in epigenetic silencing
(Gambetta et al., 2009) and, remarkably, histones are modified
by O-GlcNAc (Sakabe et al., 2010). Therefore, we propose that
HCF-1, as an adaptor protein, facilitates the recognition of
OGT substrates involved in epigenetic regulation.
Metabolism is tightly controlled by hormonal and nutritional
signals. Glucose effectiveness refers to the ability of high
glucose per se to suppress endogenous glucose production,
and it has an important role in glucose homeostasis (Tonelli
et al., 2005). Here, we describe a mechanism whereby
glucose determines its own production, which is through
regulation of OGT/HCF-1 complex formation and subsequent
O-GlcNAcylation and stabilization of PGC-1a. Compared to no
glucose, low levels of glucose stimulate gluconeogenesis; on
the other hand, hyperglycemia inhibits gluconeogenesis (Rigou-
let et al., 1987; Seglen, 1974). Consistent with this phenomenon,7, August 8, 2012 ª2012 Elsevier Inc. 233
Figure 7. Hepatic Knockdown of OGT and HCF-1 Improves Glucose
Homeostasis in Diabetic Mice
(A and B) Global O-GlcNAcylation level and OGT expression (A) and HCF-1
protein expression (B) in livers of age-matched C57BL/6 mice on normal diet
(WT andND), on high-fat diet (HFD), and db/dbmice (n = 4–5). nc andm refer to
nucleocytoplasmic and mitochondrial forms of OGT, respectively. Densito-
metric analysis is shown in Figures S7C–S7E.
(C and D) Twelve-week-old db/db male mice (n = 4–6) were infected
with shRNA adenoviruses. (C) Glucose tolerance test (day 3). (D) G6pc
mRNA expression in liver (day 7). *, #, p < 0.05; **p < 0.01 by ANOVA with
a Bonferroni’s post hoc test compared with scrambled shRNA. All values
represent mean ± SEM.
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expression of PGC-1a, enrichment of O-GlcNAc and HCF-1 on
the G6pc promoter, and expression of gluconeogenic genes all
peak under euglycemic conditions. This indicates a vital role
for the OGT/HCF-1/PGC-1a pathway in maintaining normal
glucose levels and mediating glucose effectiveness. It has
been known that loss of glucose effectiveness contributes to
type 2 diabetes (Mevorach et al., 1998). Our finding that expres-
sion of HCF-1 and BAP1 is upregulated in diabetic mice strongly
suggests that the hyperactivation of the OGT/HCF-1/PGC-1a
pathway diminishes glucose effectiveness. Hence, pharmaco-
logical inhibition of this pathway represents a potential strategy
for preventing hyperglycemia and treating type 2 diabetes.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293T cells were cultured in DMEM with 10% fetal bovine serum (FBS).
HepG2 and FAOhepatoma cells were cultured in RPMI with 10%FBS. Primary
hepatocytes were isolated by Yale Liver Center Core Facility and plated
in DMEM with 10% FBS, 2 mM sodium pyruvate, 1 mM dexamethasome,
0.1 mM insulin on Collagen I-coated plates. HEK293T and HepG2 cells were
transfected with FuGENE HD (Roche). FAO and primary hepatocytes were in-
fected with adenovirus in medium containing 0.5% BSA. Treatment with
different glucose was performed with no glucose DMEM plus 10% dialyzed
FBS and various concentrations of glucose for 6 hr. PUGNAc (10 mM, 16 hr),
MG132 (20 mM, 4 hr), and cycloheximide (100 mg/ml) were treated as indicated.
Plasmids and Adenovirus Preparation
pAdTrack, 3*IRS-luciferase, Flag-PGC-1a, and Gal4-PGC-1a plasmids were
from Addgene. pAdTrack-Flag/HA-OGT/OGA and pAdTrack-Flag-HCF-1-
Myc plasmids were constructed by subcloning of PCR products. Point
mutants of PGC-1a were generated with the QuikChange XL II Site-Directed
Mutagenesis Kit (Stratagene). OGT shRNA plasmids were purchased from
Sigma. Overexpression or shRNA adenovirus constructs were established234 Cell Metabolism 16, 226–237, August 8, 2012 ª2012 Elsevier Incusing AdEasy system (Luo et al., 2007). Adenoviruses were amplified in
HEK293 cells and purified using the kit from Virapur.
Tandem Purification and MudPIT
FH-OGT and FH-PGC-1a protein complexes were isolated from cell extracts
by immunoprecipitation with a-Flag antibody followed by a-HA antibody ac-
cording to established procedures with certain modifications (Nakatani and
Ogryzko, 2003). For the MudPIT analysis, the precipitated protein was resus-
pended and subjected to digestion with trypsin. The resulted protein digest
was pressure-loaded onto a Kasil-fritted fused silica capillary column
(250 mm i.d.) packed with 3 cm 5 mmPartisphere strong cation exchange resins
(Whatman, Clifton, NJ) and 3 cm 5 mmAquaC18 resins (Phenomenex, Ventura,
CA). After desalting, this sample-loaded back-end column was then con-
nected to a 100 mm i.d. capillary column with a 5 mm pulled tip packed with
12 cm 3 mm Aqua C18 material through a zero-dead-volume union (UpChurch
Scientific, Oak Harbor, WA), and the entire three phase column was placed in
line with an Agilent 1200 quaternary HPLC (Agilent, Palo Alto, CA) and analyzed
using a modified 11-step separation described previously. As peptides were
eluted from the microcapillary column, they were electrosprayed directly
into a hybrid LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific,
San Jose, CA) with the application of a distal 2.5 kV spray voltage. A cycle
of one FT full-scan mass spectrum (400–1400m/z, 60,000 resolution) followed
by eight data-dependent LTQ MS/MS spectra at a 35% normalized collision
energy was repeated continuously throughout each step of the multidimen-
sional separation. Application of mass spectrometer scan functions and
HPLC solvent gradients was controlled by the Xcalibur data system (Thermo
Fisher Scientific, San Jose, CA). MS/MS spectra were processed and
searched with the ProLucid algorithm (Xu et al., 2006) against the EBI human
IPI database (ftp://ftp.ebi.ac.uk/pub/databases/IPI/, version 3.30), that was
concatenated to a decoy database in which the sequence for each entry in
the original database was reversed. ProLuCID results were assembled and
filtered using the DTASelect (version 2.0) program (Cociorva et al., 2007;
Tabb et al., 2002). The MudPIT data from FH-OGT, FH-PGC-1a, and EGFP
control was compared. Proteins were designated as putative interacting
proteins if they were identified only in FH-OGT or FH-PGC-1a samples but
not in the EGFP control, or the spectral count of each protein copurified with
FH-OGT or FH-PGC-1a was at least four times larger than that in the EGFP
control.
Antibodies, Immunoprecipitation, and Western Blotting
Anti-OGT, anti-Flag, anti-HA antibodies were from Sigma. Anti-O-GlcNAc
(RL2), anti-V5 antibodies were from Abcam. Anti-HCF-1 antibody was from
Bethyl Laboratories. Anti-ubiquitin antibody was from Santa Cruz Biotech-
nology. Anti-PGC-1a (4C1.3) antibody was from EMD chemicals. Tissue and
cell proteins were lysed in 1% Nonidet P-40, 50 mM Tris,HCl, 0.1 mM
EDTA, 150 mM NaCl, proteinase inhibitors, and protein phosphatase inhibi-
tors. For immunoprecipitation, whole-cell lysates were mixed with various
antibodies as specified in the text and precipitated by Protein A/G agarose
beads (Santa Cruz). Equal amounts of whole lysates or immunoprecipitation
samples were electrophoresed on 8% SDS-PAGE gels and transferred
to PVDF membrane. Primary antibodies were incubated at 4C overnight.
Western blotting was visualized by peroxidase conjugated secondary anti-
bodies and ECL chemiluminescent substrate.
Transcriptional Activity Assay
HepG2 and FAO cells were transfected with expression plasmids,
luciferase reporters, and b-galactosidase. Cells were lysed and luciferase and
b-galactosidase enzyme activities were measured using kits from Promega.
Relative luciferase activity was determined by normalizing to b-galactosidase
activity.
Chromatin Immunoprecipitation
Primary hepatocytes were fixed with formaldehyde, lysed in buffer containing
50 mM Tris,HCl (pH 8.0), 10 mM EDTA, and 1% SDS, and then sonicated.
Soluble chromatin was diluted and then immunoprecipitated with anti-O-
GlcNAc (plus 1 M free GlcNAc as a negative control), anti-HCF-1 (H12)
antiserum, or IgG. DNA was extracted using Chelex-100 and subjected to
real-time PCR using primers flanking the FOXO1/HNF4a binding region of.
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OGT/HCF-1/PGC-1a Signaling in GluconeogenesisG6pc promoter. The 30 UTR ofG6pc was used as the negative control (Nelson
et al., 2006).
Real-Time PCR
Total RNA was extracted from cells or mouse liver using TRIzol reagent
(Invitrogen). Complementary DNAwas synthesized from total RNAwith Super-
script III enzyme and random hexamer primers (Invitrogen). cDNAs were
amplified with SYBR Green I Master and the LightCycler 480 Real-Time PCR
system (Roche). All data were normalized to the expression of 18s or 36b4.
Primer sequences are available from the authors on request.
Glucose Output Assay
Medium of primary hepatocytes or FAO cells was replaced with 1ml of
glucose-free DMEM, supplemented with 20 mM sodium lactate and 2 mM
sodium pyruvate and various glucose levels when indicated. After a 6 hr incu-
bation, medium was collected and the glucose concentration was measured
using glucose oxidation kit (Sigma). The readings were then normalized to
the total protein content. To measure gluconeogenesis, primary hepatocytes
were treated with gluconeogenic medium containing 13C pyruvate, lactate,
and different levels of glucose. Newly synthesized glucose was calculated
based on the distribution of glucose M+1 isotopomers.
Animal Studies
C57BL/6 mice were purchased from NCI/NIH, and db/db mice (Stock No.
000697) were purchased from Jackson Laboratory. Recombinant adenovirus
(63 108 plaque forming units [pfu] to C57BL/6 mice, and 23 109 pfu to db/db
mice) was delivered by systemic tail-vein injection to mice. Three to seven
days after viral infection, mice were subjected to pyruvate, glucose, and insulin
tolerance tests. Sixteen hour fasted mice were injected intraperitoneally with
sodium pyruvate (2 g/kg body weight) or glucose (1.5 g/kg body weight);
6 hr fasted mice were injected with insulin (0.75 U/kg body weight to C57BL/
6 mice, 2.5 U/kg body weight to db/db mice). Blood glucose was measured
from tail-vein blood collected at the designated times using Nova Max
Glucometer.
Statistical Analyses
Results are shown as mean ± SEM. The comparisons between two groups
were carried out using two-tailed unpaired Student’s t test. For multiple-group
comparisons, one-way ANOVAs were used to test for no differences among
the group means. Post hoc comparisons were adjusted using Bonferroni
corrections. Mixed-model ANOVAs were used to analyze data from glucose
and pyruvate tolerance tests. Covariance structure was optimized for each
data set using the Corrected Akaike Information Criterion and the Schwarz
Bayesian Information Criterion. Bonferroni corrections were employed for
post hoc comparisons (contrasts at each time period) when the global test
was significant (p < 0.05). All statistical calculations were performed in SAS
9.3 (MIXED/GLIMMIX/MULTTEST procedures).
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